Companies › Cellectar Biosciences
3 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Iopofosine I-131 (CLR 131) Radiopharmaceutical; radioiodine-131-labeled lipophilic cationic compound that localizes t | – | Phase 2 | Waldenstrom Macroglobulinemia | Dec 2027 |
| CLR 131 | – | Phase 1 | High-Grade Glioma; Pediatric Solid Tumor | Jun 2027 |
| CLR 125 Radiopharmaceutical | – | Phase 1 | Breast Cancer | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05610891 | CLR 131 | Phase 1 | High-Grade Glioma | Oncology | Jun 2027 |
| NCT03478462 | CLR 131 | Phase 1 | Pediatric Solid Tumor | Oncology | Jun 2027 |
| NCT02952508 | Iopofosine I-131 (CLR 131) | Phase 2 | Waldenstrom Macroglobulinemia | Oncology | Dec 2027 |
| NCT07311993 | CLR 125 | Phase 1 | Breast Cancer | Oncology | Feb 2028 |
Cash of $25m on 2026-09-30; operating cash outflow about $27m a year; runway about 11 months at that burn, to Aug 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
No annotated target.
–
Acrivon Therapeutics Allarity Therapeutics ALX Oncology Eikon Therapeutics CNS Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.